Mesothelioma Related Clinical Trials:
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma


    - General Info     - Purpose     - Eligibility     - Contacts & Locations     - Additional Information

Status: Completed
Sponsors and Collaborators: Eli Lilly and Company
Information provided by: Eli Lilly and Company
Government Identifier: NCT00040625

Condition: Mesothelioma
Intervention: Drug: pemetrexed; Drug: cisplatin

    - Return To Top

Purpose:


This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

    Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
  • Prior chemotherapy for your disease is allowed
  • Measurable lesion is not required
  • Have a adequate performance status
  • Sign an informed consent form

Exclusion Criteria:

  • You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
  • You are excluded from this trial if you have received radiation within the previous 2 weeks
  • You are excluded from this trial if you are a candidates for curative surgery

    - Return To Top

Eligibility:

Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

  • Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
  • Prior chemotherapy for your disease is allowed
  • Measurable lesion is not required
  • Have a adequate performance status
  • Sign an informed consent form

Exclusion Criteria:

  • You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
  • You are excluded from this trial if you have received radiation within the previous 2 weeks
  • You are excluded from this trial if you are a candidates for curative surgery

    - Return To Top

Contacts and Locations:

Please refer to this study by its ClinicalTrials.gov identifier: NCT00040625
Locations
United States, New Jersey
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Basking Ridge, New Jersey, United States
Brazil
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Sao Paulo, Brazil
Brazil, RS
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Porto Alegre, RS, Brazil
Egypt
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."
Cairo, Egypt
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Cairo, Egypt
Saudi Arabia
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Jeddah, Saudi Arabia

Sponsors and Collaborators
Eli Lilly and Company

    - Return To Top

Additional Information:

Study ID Numbers: 6093, H3E-US-JMFE
First Received: July 2, 2002
Last Updated: March 14, 2007
ClinicalTrials.gov Identifier: NCT00040625
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Folic Acid
Pemetrexed
Cisplatin
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:
Mesothelioma
Antimetabolites
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Neoplasms, Mesothelial
Antineoplastic Agents
Physiological Effects of Drugs
Enzyme Inhibitors
Folic Acid Antagonists
Pharmacologic Actions
Neoplasms
Radiation-Sensitizing Agents
Therapeutic Uses

    - Return To Top

 
 

    - Return To Top

 

    - Return To Top

 

    - Return To Top

 

    - Return To Top